Global Plant Sources Anti-Cancer Agents Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|植物源性抗癌劑的全球市場 (2020年∼2027年) Global Plant Sources Anti-Cancer Agents Market - 2020-2027|
|出版日期: 2021年05月10日||內容資訊: 英文 180 Pages||
The global plant sources anti-cancer agents market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Cancer is a major public health burden in both developed and developing countries. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Plant-derived agents are being used for the treatment of cancer. Several anticancer agents, including taxol, vinblastine, vincristine, the camptothecin derivatives, topotecan and irinotecan, and etoposide derived from epipodophyllotoxin are in clinical use all over the world. The National Cancer Institute collected about 35,000 plant samples from 20 countries and has screened around 114,000 extracts for anticancer activity. Of the 92 anticancer drugs commercially available before 1983 in the U.S. and among worldwide approved anticancer drugs between 1983 and 1994, 60% are of natural origin.
The global plant sources anti-cancer agents market growth is driven by the growing incidence of cancer cases, A number of promising agents are in preclinical or clinical development, less side effects compared to synthetic drugs.
Increasing incidence of Cancer Cases, is expected to drive the global Plant Sources Anti-Cancer Agents market during the forecast period.
According to the World Health Organisation (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. The most common cancers occurring in the U.S include lung cancer, breast cancer, prostate cancer, colorectal Cancer, thyroid cancer, pancreatic Cancer, non-Hodgkin lymphoma, melanoma, renal pelvis cancer, kidney cancer and leukemia. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. This number expected to increase the demand for plant source anti-cancer drugs.
A number of promising agents in pipeline, is expected to drive the global Plant Sources Anti-Cancer Agents market during the forecast period.
In 2021 January, AbbVie Collaborated with Sumitomo Dainippon Pharma Oncology; Inc completed Phase 1b Study of Venetoclax and Alvocidib (Flavopiridol) in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Phyton Biotech announced on June 27, 2019, that they had been granted a new patent to cover the production of Ingenol-3-angelate, Ingenol and other Ingenol esters by using our proprietary Plant Cell Fermentation PCF® technology to culture plant cells from the plant family Euphorbiaceae. The patent was granted by the United States Patent and Trade Mark Office, and its US patent number is 10,172,306. It will remain in place until March 18, 2036.
Lack of Awareness about Phytochemical agents is likely to restrict the market growth
Natural products are discovered from medicinal plants have played an essential role in the treatment of many cancers. They have exhibited anticancer action in animal models of leukemia, skin cancer and sarcomas. Generating awareness regarding the usage of herbs and exploring natural product properties, healthcare professionals and government organizations should create awareness of these drugs. They show high biodegradability and biocompatibility and can be used even in palliative care or reduce the side effects of cancer.
COVID-19 Impact Analysis
Due to the covid-19 pandemic outbreak, the market for global plant sources anti-cancer agents market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.
Based on the Type, the global plant sources anti-cancer agents segmented into Paclitaxel, Vinorelbine, Irinotecan, Hydroxycamptothecin, Docetaxel, Others.
Paclitaxel segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Paclitaxel (taxol) was first extracted from the bark and leaf of Taxus baccata (T. baccata) and T. Canadensis, Corylus avellana. First-generation taxanes (e.g., docetaxel and paclitaxel) are potent anticancer agents in their efficacy on their different molecular targets. It is used to cure a wide range of cancers, including ovarian, breast and lung cancer. The binding of paclitaxel with B-tubulin in the lumen of microtubules leads to decreased microtubule dynamics and the halt cell cycle at the M phase. For instance, Rigel Pharmaceuticals conducting Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer expected to complete by 2022.
Vinca alkaloids are the first agents introduced in clinical use. Vinorelbine is a semi-synthetic derivative of a vinca alkaloid launched in 1989 by Pierre Fabre to treat non-metastatic breast cancer and non-small cell lung cancer (NSCLC). They bind a specific site termed as tubulin heterodimers (vinca-binding site) disrupting the functions of microtubules or by arresting cell cycle at metaphase. Vinorelbine received approval by the United States Food and Drug Administration (FDA) in December 1994, sponsored by Burroughs Wellcome Company. Pierre Fabre Group now markets Navelbine in the U.S., where the drug went generic in February 2003.
Docetaxel, a semi-synthetic derivative from T. baccata, is primarily used in breast, pancreas, prostate and lung cancer therapies. The primary mechanism of taxanes is to induce microtubule stabilization, apoptotic cell death and mitotic arrest.
Irinotecan was developed by the Japanese company Yakult Honsha, is used for the treatment of colorectal cancers. It is a semi-synthetic derivative of camptothecin (family of topoisomerase I poison) is another class of plant-derived clinically-active chemotherapeutic agents that possesses strong anticancer potential inhibiting topoisomerase I in many cancers. It was first isolated from Camptotheca acuminate.
Hydroxycamptothecin the plant alkaloid camptothecin isolated from a famous Chinese tree, C. acuminata, was reported to have potent antitumor activity against leukemia cells by inhibiting the topoisomerase I.
Based on Application, the global Plant Sources Anti-Cancer Agents market is segmented into Breast cancer, Ovarian cancer, cervical cancer and Others.
The incidence of breast cancers is proliferating. According to the World Health Organization (WHO) scenario, breast cancer is the second most cancer occurring among women. It affects nearly 2.1 million women each year. The American Cancer Society's estimates for breast cancer in the United States for 2021 are that about 281,550 new cases of invasive breast cancer will be diagnosed in women. According to Breast Cancer Care, WA Incorporated in 2019; an estimated 19,371 Australian women were diagnosed with the breast cancer or approximately 53 each day, which accounts for roughly 14% of all new breast cancer cases are diagnosed; furthermore, according to Cancer Research UK, breast cancer is the most common cancer in United Kingdom, accounting for nearly 15% of all the new cancer cases.
Based on Distribution channel, the global plant sources anti-cancer agents market segmented into hospital pharmacies, retail pharmacies, online pharmacies and others.
The hospital pharmacies held the largest share in the global colorectal cancer drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.Also the medications can only be administrated by intravenously under supervision of medical practioners at these locations.
North America served the largest share of the market due to the increasing prevalence of cancer diseases. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020.The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and many companies are developing oncology products.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, A Phase II, Study of Albumin-bound Paclitaxel Combination with Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer by Fudan University.
The global plant sources anti-cancer agents market is quite competitive with some key competitors like Phyton Biotech, ScinoPharm, Samyang, Novasep, Huiang biopharma, TAPI (Teva), Fresenius-kabi, Pfizer, West-Ward Pharmaceuticals, Jiangsu Yew Biotechnology. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, Huiang Biochemistry Pharmaceutical Co Ltd was founded in August 1998 and has been specially engaged in extracting and developing taxanes products with Paclitaxel drug substance (API) and docetaxel drug substance (API) as its leading products.
Company Overview: Phyton Biotech began in 1990, developing manufacturing solutions for complex natural phytochemicals using Plant Cell Fermentation (PCF®) Technology. Phyton Biotech is the world's largest producer of high-quality paclitaxel and docetaxel via Plant Cell Fermentation (PCF®) technology. Phyton is a subsidiary of DFB Pharmaceuticals. In 2003, Phyton was acquired by DFB Pharmaceuticals; it continued to advance PCF® to express a recombinant protein for enzyme replacement therapy that was advanced to a pre-clinical trial by 2007. In late 2009, Phyton acquired the assets of Natural Pharmaceuticals, Inc. In 2012, Phyton launched its own commercial oncology API business, selling paclitaxel and docetaxel globally.
Product Portfolio: The Company's portfolio also offers comprehensive development services for biopharmaceuticals and phytochemicals using PCF®, serving the Pharmaceutical, Cosmetic, Agricultural and Food Ingredient industries.
On January 31st, 2019, Phyton Biotech Partners with Pelle Pharm to Develop Renewable Supply of Cyclopamine for Investigational Topical Cancer Therapy.
The global plant sources anti-cancer agents market report would provide an access to an approx. market data 61 tables, 57 figures and 240 pages.
LIST NOT EXHAUSTIVE